Intrathecal baclofen management of poststroke spastic hypertonia: Implications for function and quality of life
Intrathecal baclofen management of poststroke spastic hypertonia: Implications for function and quality of life
复制标题
DOI：
10.1016/j.apmr.2006.08.323
复制
发表时间：
2006-11-01
影响因子：
4.3
通讯作者：
Grissom, Samuel P.
中科院分区：
文献类型：
--
作者：
Ivanhoe, Cindy B.;Francisco, Gerard E.;Grissom, Samuel P.
目的：评估鞘内注射巴氯芬（ITB）对功能和生活质量（QOL）的影响，并获得卒中后痉挛性肌张力增高的疗效和安全性数据。设计：前瞻性开放标签多中心试验，随访3个月和12个月。设置：美国24个卒中治疗中心。参与者：94名患有痉挛性肌张力增高的卒中受试者（年龄范围，24- 82岁）。74名受试者接受了ITB泵植入术。干预：受试者植入了ITB泵。主要结局指标：血糖仪和生活质量（疾病影响特征[SIP]）变化，痉挛性张力亢进（Ashworth量表）和安全性。结果：在重复测量方差分析（ANOVA）中，平均得分总体改善（P=.005）和3.00 +/- 7.69（P=.001）在3个月和2.86 +/- 10.13（P=.017）在12个月。总体上观察到SIP评分的显著改善（重复测量ANOVA，P
Objectives: To evaluate the impact of intrathecal baclofen (ITB) on function and quality of life (QOL) and to obtain efficacy and safety data in poststroke spastic hypertonia.Design: Prospective open-label multicenter trial with follow-up at 3 and 12 months.Setting: Twenty-four stroke treatment centers in the United States.Participants: Ninety-four stroke participants (age range, 24-82y) with spastic hypertonia. Seventy-four participants underwent ITB pump implantation.Intervention: Participants were implanted with an ITB pump.Main Outcome Measures: FIM instrument and QOL (Sickness Impact Profile [SIP]) changes, spastic hypertonia (Ashworth Scale), and safety.Results: FIM scores improved overall in repeated-measures analysis of variance (ANOVA) (P=.005) and by 3.00 +/- 7.69 (P=.001) at 3 months and by 2.86 +/- 10.13 (P=.017) at 12 months. Significant improvements in SIP scores were noted overall (repeated-measures ANOVA, P